Tracer library / [177Lu]Lu-Evans

[177Lu]Lu-Evans

Also written as [Lu-177]Lu-Evans

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Dosimetry and biodistribution studies FAP-directed radioligand therapy Sarcoma (soft tissue and bone)

What it is

Compound class: FAP-targeted radiopharmaceutical (Evans blue-modified FAPI conjugate)
Target / mechanism: Fibroblast activation protein (FAP) PMID 40049742
Clinical application: Recurrent or metastatic solitary fibrous tumor PMID 40049742
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy.
2025 · J Nucl Med · Clinical study
Preclinical and First-in-Human Study of a Compact Radionuclide Labeled Self-Assembly Nanomedicine for Chemo-Radio-Theranostics of Cancer.
2025 · ACS Nano · Clinical study

Need this precursor?We can point you to suppliers for [177Lu]Lu-Evans, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'investigational'; normalised to 'Clinical research', original wording kept here.